Furmonertinib is named as an intervention in 20 current clinical trials in our China, UK and USA registers. 14 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is ArriVent BioPharma, Inc (2). The most-studied condition is Non-small Cell Lung Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Non-small Cell Lung Cancer | 4 |
| Non-Small Cell Lung Cancer | 4 |
| NSCLC | 3 |
| Metastatic Non-Small Cell Lung Cancer | 2 |
| Advanced Non-Small Cell Lung Cancer | 2 |
| EGFR Gene Mutation | 2 |
| Non Small Cell Lung Cancer | 2 |
| Non-Small Cell Lung Cancer (NSCLC) | 1 |
| HER2 Exon 20 Mutations | 1 |
| EGFR Exon 20 Mutations | 1 |
| Leptomeningeal Metastasis | 1 |
| Non-small Cell Lung Cancer (NSCLC) | 1 |
| Brain Metastases | 1 |
| Furmonertinib | 1 |
| EGFR Mutation | 1 |
| Advanced Lung Cancer | 1 |
| Non-Small-Cell Lung Cancer | 1 |
| Non-small Cell Lung Carcinoma | 1 |
| ALK Gene Mutation | 1 |
| ROS1 Gene Mutation | 1 |
| Non Small Cell Lung Cancer NSCLC | 1 |
| Lead sponsor | Trials |
|---|---|
| ArriVent BioPharma, Inc. | 2 |
| Henan Cancer Hospital | 2 |
| Allist Pharmaceuticals, Inc. | 2 |
| Hunan Province Tumor Hospital | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| Tang-Du Hospital | 1 |
| Shanghai Pulmonary Hospital, Shanghai, China | 1 |
| InxMed (Shanghai) Co., Ltd. | 1 |
| Minghui Pharmaceutical (Hangzhou) Ltd | 1 |
| Changhai Hospital | 1 |
| Second Affiliated Hospital of Nanchang University | 1 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 1 |
| Jialei Wang | 1 |
| Sun Yat-sen University | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 20 | 14 |
| Clinical trials in UK | 2 | 0 |
| Clinical trials in USA | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
20 current trials in our China, UK and USA registers name Furmonertinib (also registered as AST2818) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 14 of the 20 trials are recruiting: 14 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
ArriVent BioPharma, Inc (2), Henan Cancer Hospital (2), Allist Pharmaceuticals, Inc (2) and Hunan Province Tumor Hospital (2), among 15 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Furmonertinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Furmonertinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Furmonertinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.